
Nanosanguis S.A.
Research and experimental development in natural sciences and engineering
Overview
Nanosanguis is a biotechnology company focused on utilizing nanotechnology in medicine, specifically in the fields of transplantation and transfusion. It aims to increase the availability of organs for transplantation by developing innovative organ perfusion systems and a safe, effective blood substitute. The company also seeks to enhance organ preservation methods and expand the donor pool by utilizing kidneys from donors after circulatory death.
Financials
Revenue history (in k)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.
From the notes
| Profit allocation | Loss to be covered | |
| Management board pay | $200,904 | |
| Deferred tax assets | $3,885,021 | |
| Shareholders |
|
Filing timeliness
1 of 6 financial statements was filed late (for 2023, 21 days late). All were audited by a statutory auditor.
- 202514/07/2026
- 202414/07/2025
- 202305/08/2024
- 202206/07/2023
- 202130/06/2022
- 202002/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Organ perfusion research
- Organ perfusion system
- Organ regeneration
- Blood substitute preparation
- Nanomedicine technologies
Website technology
- Online shop
- WooCommerce
- Website
- WordPress
- Analytics and marketing
- Google Analytics
Authorized Representatives
Manner of representation
In the case of a one-person management board, the President of the Management Board is authorized to make declarations of will on behalf of the company and to represent the company. If a multi-member management board is appointed, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to perform legal acts and make declarations on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2016-01-29.
55 1950 0001 2006 0017 4959 0004
28 1950 0001 2006 0017 4959 0005
82 1950 0001 2006 0017 4959 0003
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 19, 2017 | Commercial Companies Code notice | |
| Apr 19, 2016 | Commercial Companies Code notice |
Public aid
17 public aid cases recorded, with a total value of $9,945,966.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Aug 5, 2025 | Aid for research and development projects: industrial research | $3.9M$3,922,151 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Aug 5, 2025 | Aid for research and development projects: experimental development | $1.7M$1,686,318 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Apr 24, 2025 | Aid for research and development projects: industrial research | $507K$506,972 | Prezes Agencji Badań Medycznych |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $7,415,789.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-11-01 | NanOX 4 Kidney – next-generation kidney perfusion fluid based on a synthetic oxygen carrier | $5.6M$5,595,822 | European Funds for a Modern Economy | |
| 2020-07-15 | Development of a significantly improved device for normothermic organ perfusion in the field of transplantation. | $82,825$82,825 | Operational Programme Smart Growth | |
| 2016-10-01 | OrganFarm – a system for the long-term storage of organs ex vivo | $1.3M$1,311,841 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Scope Fluidics S.A. | $1,264,188.85 | scopefluidics.com | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Famicordtx S.A. | $589,673.84 | famicordtx.com | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Bactrem sp. z o.o. | $181,958.36 | bactrem.pl | ||
| Biotts S.A. | $159,262.71 | biotts.com | ||
| Personather sp. z o.o. | $47,478.47 | personather.pl | ||
| Orphinic Scientific S.A. | $42,972.42 | orphinic.com | ||
| DR Joanna Sanford sp. k. | $28,674.82 | sanfordbiotech.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-09-16 | Switch to PKD 2025 (7 PKD 2007 codes → 5 PKD 2025 codes) | |
| 2025-01-24 | Share capital increase (3,888,560.00 PLN → 4,068,587.00 PLN) | |
| 2024-07-10 | Share capital increase (3,788,560.00 PLN → 3,888,560.00 PLN) | |
| 2024-02-13 | Share capital increase (3,343,560.00 PLN → 3,788,560.00 PLN) | |
| 2023-06-12 | Share capital increase (1,278,756.00 PLN → 3,343,560.00 PLN) |
FAQ
Last updated: 2026-07-17